Non-neoplastic portal vein thrombosis

1. Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 2019; 156(6): 1582–1599.e1.

2. Sarin SK, Sollano JD, Chawla YK, et al. Members of the APASL working party on portal hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26(5): 512–519.

3. Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31(3): 587–591.

4. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41(3): 603–608.

5. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology 2010; 51(1): 210–218.

6. Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood 2012; 120(25): 4921–4928.

7. Peniket AJ. The myeloproliferative disorders. CPD Bull Cell Pathol 2002; 4(1): 35–38.

8. Turon F, Cervantes F, Colomer D, et al. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol 2015; 62(1): 72–74.

9. Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: A systematic review and meta–analysis of observational studies. J Gastroenterol Hepatol 2013; 28(3): 432–442.

10. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis: A meta-analysis. Thromb Haemost 2008; 99(4): 675–682.

11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295–306.

12. Levine J, Branch D, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346(10): 752–763.

13. Qi X, De Stefano V, Su C, et al. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: A systematic review with meta-analysis. Med (United States) 2015; 94(4).

14. Landman C, Nahon S, Cosnes J, et al. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(3).

15. Rebours V, Boudaoud L, Vullierme MP, et al. Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. Am J Gastroenterol 2012; 107(10): 1579–1585.

16. Condat B, Pessione F, Denninger H, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32(3): 466–470.

17. Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): Diagnosis and management in the modern era. Clin Infect Dis 1995; 21(5): 1114–1120.

18. Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42(3): 163–170.

19. Elkrief L, Corcos O, Bruno O, et al. Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. Liver Int 2014; 34(9): 1314–1321.

20. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120(2): 490–497.

21. Orr DW, Harrison PM, Devlin J, et al. Chronic Mesenteric Venous Thrombosis: Evaluation and Determinants of Survival During Long-Term Follow-up. Clin Gastroenterol Hepatol 2007; 5(1): 80–86.

22. Chawla Y, Dilawari JB. Anorectal varices – Their frequency in cirrhotic and non-cirrhotic portal hypertension. Gut 1991; 32(3): 309–311.

23. Handa P, Crowther M, Douketis JD. Portal vein thrombosis: A clinician–oriented and practical review. Clin Appl Thromb 2014; 20(5): 498–506.

24. Mínguez B, García-Pagán JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 2006; 43(4): 707–714.

25. Dhiman RK, Behera A, Chawla YK, et al. Portal hypertensive biliopathy. Gut 2007; 56(7): 1001–1008.

26. Condat B, Vilgrain V, Asselah T, et al. Portal cavernoma-associated cholangiopathy: A clinical and MR cholangiography coupled with MR portography imaging study. Hepatology 2003; 37(6): 1302–1308.

27. Llop E, De Juan C, Seijo S, et al. Portal cholangiopathy: Radiological classification and natural history. Gut 2011; 60(6): 853–860.

28. Bradbury MS, Kavangh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. Radiographics 2002; 22(3): 527–541.

29. de Gaetano AM, Lafortune M, Patriquin, et al. Cavernous transformation of the portal vein: Patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. Am J Roentgenol 1995; 165(5): 1151–1155.

30. Vilgrain V, Condat B, Bureau C, et al. Atrophy-hypertrophy complex in patients with cavernous transformation of the portal vein: CT evaluation. Radiology 2006; 241(1): 149–155.

31. Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64(1): 179–202.

32. Morasch MD, Ebaugh JL, Chiou AC, et al. Mesenteric venous thrombosis: A changing clinical entity. J Vasc Surg 2001; 34(4): 680–684.

33. Schoots IG, Koffeman GI, Legemate DA, et al. Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. Br J Surg 2004; 91(1): 17–27.

34. Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis – 1911 to 1984. Surgery 1987; 101(4): 383–388.

35. Spaander MCW, Hoekstra J, Hansen BE, et al. Anticoagulant therapy in patients with non–cirrhotic portal vein thrombosis: Effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost 2013; 11(3): 452–459.

36. Ferreira CN, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 2016; 63(5): 1640–1650.

37. Turnes J, García-Pagán JC, González M, et al. Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. Clin Gastroenterol Hepatol 2008; 6(12): 1412–1417.

38. De Franchis R. Abraldes JG, Bajaj J, et al. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63(3): 543–545.

39. Kanellopoulou T, Alexopoulou A, Theodossiades G, et al. Pylephlebitis: An overview of non–cirrhotic cases and factors related to outcome. Scand J Infect Dis 2010; 42(11–12): 804–811.

40. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007; 102(11): 2464–2470.

41. Spaander MCW, Murad SD, van Buuren HR, et al. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc 2008; 67(6): 821–827.

42. Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010; 139(4).

43. Hall TC, Garcea G, Metcalfe M, et al. Management of acute non-cirrhotic and non-malignant portal vein thrombosis: A systematic review. World J Surg 2011; 35(11): 2510–2520.

44. Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005; 16(5): 651–661.

45. Fanelli F, Angeloni S, Salvatori FM, et al. Transjugular intrahepatic portosystemic shunt with expanded–polytetrafuoroethylene- covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis 2011; 43(1): 78–84.

46. Luo X, Nie L, Zhou B, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract 2014; 2014: 659726.

47. Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011; 54(1): 78–88.

48. Kumar S, Sarr M, Kamath P. Mesenteric venous thrombosis. N Engl J Med 2001; 345(23): 1683–1688.

49. Khanna R, Sarin SK. Non-cirrhotic portal hypertension – Diagnosis and management. J Hepatol 2014; 60(2): 421–441.

50. Ögren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23796 consecutive autopsies. World J Gastroenterol 2006; 12(13): 2115–2119.

51. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012; 57(1): 203–212.

52. Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology 2015; 61(2): 660–667.

53. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes. Am J Gastroenterol 2013; 108(4): 568–574.

54. Tripodi A, Mannucci PM. The Coagulopathy of Chronic Liver Disease. N Engl J Med 2011; 365(2): 147–156.

55. Wu X, Yao Z, Zhao L, et al. Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis. Liver Int 2016; 36(12): 1800–1810.

56. Zuwała-Jagiełło J, Simon KA, Pazgan-Simon M. Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report. Clin Exp Hepatol 2015; 1(3): 105–111.

57. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51(4): 682–689.

58. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40(5): 736–741.

59. D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38(3): 599–612.

60. Tublin ME, Dodd GD, Baron RL. Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. Am J Roentgenol 1997; 168(3): 719–723.

61. Rossi S, Rosa L, Ravetta V, et al. Contrast-enhanced versus conventional and color doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. Am J Roentgenol 2006; 186(3): 763–773.

62. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 2005; 54(5): 691–697.

63. Englesbe MJ, Schaubel DE, Cai S, et al. Portal vein thrombosis and liver transplant survival benefit. Liver Transplant 2010; 16(8): 999–1005.

64. Rodríguez-Castro KI, Porte RJ, Nadal E, et al. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: A systematic review. Transplantation 2012; 94(11): 1145–1153.

65. Hibi T, Nishida S, Levi DM, et al. When and why portal vein thrombosis matters in liver transplantation: A critical audit of 174 cases. Ann Surg 2014; 259(4): 760–766.

66. Vianna RM, Mangus RS, Fridell JA, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis. Ann Surg 2012; 255(6): 1144–1150.

67. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 2005; 54(5): 691–697.

68. Delgado MG, Seijo S, Yepes I, et al. Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol 2012; 10(7): 776–783.

69. Rodriguez-Castro KI, Vitale A, Fadin M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31(1): 34–42.

70. Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 153(2): 480–487.

71. Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64(1): 179–202.

72. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143(5): 1253–1260.e4.

73. Senzolo M, Rodriguez-Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10(9): 1823–1829.

74. Weinberg EM, Palecki J, Reddy KR. Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis–Associated Portal Vein Thrombosis. Semin Liver Dis 2019; 39(2): 195–208.

75. Perarnau JM, Baju A, D’alteroche L, et al. Feasibility and longterm evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol 2010; 22(9): 1093–1098.

76. Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23(6): 767–775.